WXXWY WUXI BIOLGCS ADR
- 4.230
- -0.300-6.62%
WUXI BIOLGCS ADR News
Trump Government Likely to Still Pass Biosecure Act -- Market Talk
Abnormal movements | The CRO concept is generally rising, with medical insurance negotiations supporting innovative drugs. Global biomedical financing will rebound in an environment of interest rate cuts.
The concept of CRO is generally on the rise. As of the time of publication, Asymchem Laboratories rose by 4.95%, to 59.4 Hong Kong dollars; Tigermed rose by 5.21%, to 38.35 Hong Kong dollars; WuXi AppTec rose by 3.69%, to 53.4 Hong Kong dollars.
Mainland medical insurance pharmaceutical catalog adjustment negotiations are expected to end, and the new version of the catalog is expected to be released by the end of the month.
According to a report by the People's Daily, following the established work arrangements, from October 27th to 30th, under the organization of the National Medical Insurance Bureau, 25 negotiating experts from various provincial medical insurance departments conducted on-site negotiations and bidding with 127 enterprises, involving 162 types of pharmaceuticals, including 117 types of pharmaceuticals outside the medical insurance catalog and 45 types of pharmaceuticals within the negotiated renewal in the medical insurance catalog. This year's on-site negotiation work progressed smoothly and steadily, with overall results basically consistent with previous years, meeting expectations. The new version of the medical insurance pharmaceutical catalog after the “expansion” is expected to be released to the public at the end of November, and will be officially implemented starting next year. Relevant to the National Medical Insurance Administration's Pharmaceutical Service Management Department.
Shanghai will lower prices for certain veterinary services starting on Friday.
Shanghai Health Insurance Bureau and Shanghai Health Commission issued a notice on reducing prices of some veterinary services in the city. Among them, the prices of some veterinary services such as Thromboelastography Test (TEG) will be reduced to encourage institutions to strengthen management and reduce costs. The notice will be effective from this Friday, November 1st.
Wuxi bio launches the technology platform WuXia RidGS, empowering customers to develop non-antibiotic cell lines.
shanghai, October 28, 2024 / PRNewswire/ -- global leading Contract Research, Development, and Manufacturing Organization (CRDMO) company wuxi bio (WuXi Biologics, 2269.HK) announced the launch of WuXia RidGS cell line construction platform based on high-yield glutamine synthetase (GS) in Chinese hamster ovary (CHO) expression system. This platform is a research and development platform for non-antibiotic cell lines, utilizing Zinc Finger Nuclease (ZFN) technology to knock out the endogenous GS gene in CHO cells. WuXia RidGS is derived from
The first batch of pharmaceutical fund's third quarter report is released! Shareholding in US stocks reduced, while increasing holdings in Hong Kong stocks and A-shares.
The first batch of fund managers exposed in the third quarter medical investment strategy, significantly increased the proportion of innovative drugs, especially the position of Hong Kong-listed innovative drugs with greater flexibility.
HK Stocks Update: Pharmaceutical stocks continue to strengthen, AstraZeneca-B (01541) expands its gains in the afternoon. Hong Kong approval mechanism will be extended to all new drugs starting from November.
Pharmaceutical stocks continue to strengthen, as of the time of publication, Wuxi Bio-B (01541) rose 22.76%, to 7.65 Hong Kong dollars; Zai Lab (09688) rose 15.25%, to 25.7 Hong Kong dollars; Hoyo-B (02256) rose 8.82%, to 4.32 Hong Kong dollars; Tigermed (03347) rose 11.65%, to 41.2 Hong Kong dollars; Wuxi Bio (02269) rose 6.68%, to 17.56 Hong Kong dollars.
Department of Health: The "1+" approval mechanism will be expanded to all new drugs starting from November, embodying the concept of "Hong Kong, a Good Drug Harbor".
The Department of Health announced today (25th) that, in accordance with the measures announced in the Chief Executive's Policy Address for 2024, the "1+" approval mechanism will be expanded to all new drugs starting from November 1 this year, including vaccines and advanced therapy products, embodying the concept of "good medicine available in Hong Kong." Expanding the "1+" mechanism can attract more new drugs from around the world to register in Hong Kong, providing patients with more choices, strengthening the local drug regulatory capacity, promoting the development of relevant hardware and software, and talent, and further moving towards the "first-level approval." The government will innovate the system in conjunction with technological innovation to develop Hong Kong into an international medical innovation hub. According to the "Pharmacy and Poisons Ordinance".
Hong Kong stock market midday review | The three major indices collectively climbed! The technology index rose by nearly 2%; photovoltaic stocks led the gains, lithium battery stocks rose, GCL Tech surged more than 23%, and Ganfeng Lithium rose by nearly
Network technology stocks rise, Xiaomi Group-W up 3.37%, SenseTime-W up 2.52%; lithium battery stocks up across the board, Ganfeng Lithium up 10.73%, Tianqi Lithium Corporation up 10.60%; semiconductor stocks generally rise, Solomon Systech up 7.14%, Hua Hong Semi up 5.84%.
Abnormal movement hits the CRO concept in the morning, driven by innovative drug policies and expectations of Fed rate cuts, Pharmaron and Tigermed both rose more than 7%.
CRO concept rose in the morning, as of the time of publication, Frontage Holdings increased by 8.45%, Pharmaron increased by 7.64%, Tigermed increased by 7.99%, and Joinn Laboratories increased by 5.59%.
Wuxi Bio [02269] is now trading at 17.3 Hong Kong dollars, with a rise of 5.10%.
As of 10:50, Wuxi Bio [02269] reported a share price of 17.3 Hong Kong dollars, up 0.84 Hong Kong dollars or 5.10% from the previous closing price of 16.46 Hong Kong dollars, with a turnover of 458.7831 million Hong Kong dollars. The highest price today is 17.3 Hong Kong dollars, and the lowest price is 16.42 Hong Kong dollars. Based on the closing price from yesterday, the 10-day average price is 16.49 Hong Kong dollars, the 50-day average price is 13.77 Hong Kong dollars, and the current PE ratio is 18.29 times. The 14-day relative strength index is reported as 42.09.
National Healthcare Security Administration: Negotiations on healthcare will be held in Beijing next week, with adjusted results expected to be announced next month.
According to CCTV, it was learned from the National Medical Insurance Administration that the on-site negotiation/bidding of the medical insurance catalog for 2024 will be held in Beijing from Sunday (the 27th) to next Wednesday (the 30th) as per the work arrangement. The adjustment results are expected to be announced in November, and the new version of the pharmaceutical catalog will be implemented starting next year. According to the "Work Plan for the Adjustment of the National Medical Insurance Pharmaceutical Catalog in 2024", the seventh adjustment of the national medical insurance pharmaceutical catalog since the establishment of the National Medical Insurance Administration officially started in July. After formal review, expert evaluation, and result confirmation, a total of 162 generic pharmaceuticals have been confirmed to participate in negotiations/bidding.
Hong Kong stock market anomaly | CRO concept stocks collectively rise. The segmented production trial work plan for biological products will be released in the near future.
CRO concept stocks collectively rose, as of the time of publication, frontage (01521) rose by 13.79%, to 0.66 Hong Kong dollars; genscript bio (01548) rose by 4.75%, to 12.36 Hong Kong dollars; pharmaron (03759) rose by 3.68%, to 15.2 Hong Kong dollars.
The tenth batch of national pharmaceutical collection and procurement volume reporting work in mainland China has been initiated, involving 62 varieties, with injections accounting for over half.
According to internal media reports, with the recent conclusion of the tenth batch of national organized pharmaceutical joint procurement conference, the work of reporting the tenth batch of national pharmaceutical joint procurement officially started today (18th). Shanxi Province Pharmaceutical Centralized Competitive Bidding Procurement Network issued the "Notice on Submitting the Demand Quantity of the Tenth Batch of National Organized Pharmaceutical Centralized Procurement Varieties" on Wednesday (16th), with the deadline for medical institutions to report from October 18th to 28th, using an online direct reporting method. When the reported quantity of medical institutions is less than 80% of their historical procurement volume, an explanation is required. For medical institutions with historical procurement volumes that do not participate in reporting quantities, monitoring will be enforced in the later stage.
Hong Kong stock market anomaly | CRO concept stocks are all rebounding, with many stocks rising by more than 10%. The National Medical Products Administration has deployed a pilot reform of segmented production of biological products.
CRO concept stocks rebounded across the board, as of the time of publication, frontage (01521) rose 14%, closing at 0.57 Hong Kong dollars; pharmaron (03759) rose 12.59%, closing at 14.84 Hong Kong dollars; tigermed (03347) rose 11.11%, closing at 38 Hong Kong dollars; wuxi bio (02269) rose 10.54%, closing at 16.78 Hong Kong dollars.
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
Hong Kong's large cap index further widened, Hang Seng Index rose by 3.44%, Meituan (03690) rose by 8.93%.
Jingu Financial News | The Hang Seng large cap index further expanded by 3.44%, the Hang Seng China Enterprises Index rose by 3.89%, and the Hang Seng Tech Index surged by 5.8%. Semiconductor Manufacturing International Corporation (00981) led the gains in blue chips with a 15.96% increase. In addition, BYD Electronic (00285) rose by 9.32%, Wuxi Bio (02269) rose by 9.22%, and Ali Health (00241) rose by 8.63%. In the ATMX, Meituan (03690) rose by 8.93%, Xiaomi Group (01810) rose by 5.61%, Tencent (00700) rose by 4.65%, Alibaba (09988) rose
WuXi Biologics Receives ESG Corporate Platinum Award From The Asset for Fourth Consecutive Year
WuXi Biologics Receives ESG Corporate Platinum Award From The Asset for Fourth Consecutive Year
HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has
Express News | China Securities Co.,Ltd.: Focus on investment opportunities in seven directions in the health care industry.
Analysis
Price Target
No Data
No Data